C-Path European Nonprofit Established in Amsterdam
C-Path in Europe works seamlessly with its U.S. counterpart to advance the development of novel regulatory-endorsed methodologies to accelerate medical product developmentContinue reading
Category Archives: AZBio News
Life365 Partners with Microsoft Cloud for Healthcare to Empower Providers and Payors to Transition Care to Low-Cost Settings – Home
Scottsdale, AZ, March 22, 2022— Life365, a Microsoft Partner and leading Virtual Care and Remote Patient Monitoring (RPM) platform, announced today the integration into Microsoft Cloud for Healthcare, empowering Providers and Payors to connect and scale to larger patient populations in low-cost settings, typically at home.Continue reading
Could diet modification make chemotherapy drugs more effective for patients with pancreatic cancer?
Laboratory experiments at Princeton University and TGen, testing a ketogenic diet, lead to nationwide clinical trial
Are You Ready for the Rise in Virtual Care (Guest Post by LIFE365)
The rise in virtual care has opened the door for healthcare delivery transformation. This rise can be linked back to the pandemic, and new reimbursement opportunities for remote care services, which have fueled the adoption of digital health technologies, including remote patient monitoring.Continue reading
Arizona Commerce Authority offering a registration reimbursement grant for TechConnect Conference 2022
TechConnect is the premier SBIR conference where companies across the country gather to hear from experts and connect directly with SBIR program managers. Many companies credit the experience and knowledge they gained from attending with helping them submit a successful SBIR application.
The Arizona Commerce Authority understands that the cost of travel and accommodations may not be feasible for everyone, so they are offering a registration reimbursement
HTG Molecular Diagnostics Announces $7.5 Million Private Placement
TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.
TGen, HonorHealth and Irish biomedical firm initiate promising ‘Nieto’ clinical trial against pancreatic cancer
Named for a respected Arizona scientist, this trial uses a combination of drugs against advanced cancer in patients where other treatments have failed
Nearly 100 Organizations and Experts Urge HHS Secretary Xavier Becerra to Reject Xtandi March-In Petition
WASHINGTON, D.C. (March 17) — In a letter transmitted today, the Bayh-Dole Coalition and nearly 100 prominent academic and private sector innovation experts and organizations, public policy associations, and legal scholars urged U.S. Department of Health and Human Services Secretary Xavier Becerra to reject the latest march-in petition on prostate cancer drug Xtandi.Continue reading
BioTech Company PathogenDx Strengthens Executive Team; Announces Several New Key Leadership Appointments
PathogenDx Appoints Foremost Industry and Topic Experts as Its Advanced Microarray Testing Platform Sets New Standards in DNA-Based TestingContinue reading
Ivy Brain Tumor Center Opens New Clinical Trial for Patients with Recurrent Grade IV Gliomas
Study offers therapeutic expansion phase for patients with a positive pharmacokinetic response to investigational drug